


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



IN RE APPLICATION OF: Mark David Fidock

1/17/02
#6 T. Gray

APPLICATION NO.: 09/471,459

: Examiner: P. Duffy

FILING DATE: December 22, 1999

: Group Art Unit: 1645

TITLE: Enzymes PDE xiv

:

TECH CENTER 1600/2900

Director – U.S. Patent and Trademark Office
Washington, D.C. 20231

RECEIVED

JAN 03 2001

PRELIMINARY AMENDMENT

Attached hereto is a replacement specification. During preparation of the sequence listing, it was determined that numerous amino acid and nucleotide sequences were present in the original specification and had not been included in the original written sequence listing. These sequences needed to be included and given SEQ ID NOs in the specification. Rather than try to provide numerous individual replacement sheets, the attached specification replaces the original specification in full.


Applicant hereby attests that the replacement specification contains no new matter and is identical to the original specification, with the exception that amino acid and nucleotide sequences were supplemented with accurate SEQ ID NOs corresponding to those in the sequence listing also submitted herewith. Additionally, original sequences labeled SEQ ID NOs:5, 6, and 9 were modified. Original SEQ ID NOs:5 and 6 were actually comparisons of original sequences with previously presented sequences. As this is not proper for U.S. sequence listing requirements, the comparison sequence was deleted and only the original sequence presented. With respect to original SEQ ID NO:9, this was actually a sequence formula, also referred to as Formula I throughout the specification. Again, as this is not a proper format for a U.S. sequence listing, Formula I is no longer referred to as SEQ ID NO:9 anywhere in the specification, and only the term Formula I is used.

Again, the replacement specification contains no new matter, but merely supplies appropriate sequence identification numeration to sequences provided with the original

specification. If any further clarification is required, the Examiner is invited to call Applicant's agent at the number indicated hereinbelow.

Date: 12/20/01

Respectfully submitted,



Gregory P. Raymer
Attorney for Applicant(s)
Reg. No. 36,647

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5746

Express Mail No. EL911725645US